A lack of novel excipients is threatening the ability of drug developers to translate progress with small molecules and biologics into therapeutic success. The FDA could soon test a new model of excipient review to foster formulation innovation.

中文翻译：

---

辅料开发商呼吁对法规进行改造

缺乏新型赋形剂正威胁着药物开发人员将小分子和生物制剂的进展转化为治疗成功的能力。FDA可能很快会测试一种新的辅料审查模型，以促进配方创新。